Feasibility of Engaging and Capturing Undiagnosed Myasthenia Gravis Participants Through a Social Media Campaign Paired With a Self-moderated Assessment
Conditions: Myasthenia Gravis; Neuromuscular Manifestations; Neuromuscular Diseases Interventions: Behavioral: Social media recruitment; Behavioral: Self-Assessment; Behavioral: Follow-up Sponsors: ZS Associates; University of California, San Francisco Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
Safety and Efficacy of CD19-BCMA Targeted CAR-T Therapy for Refractory Generalized Myasthenia Gravis
Conditions: Myasthenia Gravis Interventions: Drug: CD19-BCMA Targeted CAR-T Dose 1; Drug: CD19-BCMA Targeted CAR-T Dose 2; Drug: CD19-BCMA Targeted CAR-T Dose 2 Sponsors: Ting Chang, MD Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
Conditions: Generalized Myasthenia Gravis (gMG) Interventions: Biological: CABA-201 Sponsors: Cabaletta Bio Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
Immediate Corticosteroid Therapy and Rituximab to Prevent Generalization in Ocular Myasthenia: a PROBE Multicenter Open-label Randomized Controlled Trial.
Conditions: Ocular Myasthenia Gravis Interventions: Drug: immediate treatment with corticosteroids; Drug: addition of rituximab if recurrence Sponsors: Fondation Ophtalmologique Adolphe de Rothschild Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
Study of Ultomiris ® (Ravulizumab) Safety in Pregnancy
Conditions: Ultomiris-exposed Pregnant/ Postpartum; Pregnancy; Paroxysmal Nocturnal Hemoglobinuria (PNH); Atypical Hemolytic Uremic Syndrome (aHUS); Generalized Myasthenia Gravis (gMG); Neuromyelitis Optica Spectrum Disorder (NMOSD) Interventions: Other: Ultomiris Sponsors: Alexion Pharmaceuticals, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
A Worldwide Pregnancy Safety Study to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to Efgartigimod During Pregnancy and/or Breastfeeding.
Conditions: Myasthenia Gravis Interventions: Biological: Efgartigimod Sponsors: argenx Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 8, 2024 Category: Research Source Type: clinical trials
A Phase 3 Study to Evaluate the Efficacy and Safety of Efgartigimod IV in Patients With Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis
Conditions: Generalized Myasthenia Gravis Interventions: Biological: Efgartigimod IV; Other: Placebo IV Sponsors: argenx Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2024 Category: Research Source Type: clinical trials
A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa
Conditions: Myasthenia Gravis Interventions: Biological: efgartigimod Sponsors: argenx Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 7, 2024 Category: Research Source Type: clinical trials
A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
Conditions: Myasthenia Gravis, Generalized Interventions: Drug: DNTH103; Drug: Placebo Sponsors: Dianthus Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 28, 2024 Category: Research Source Type: clinical trials
Physical Activity Monitoring in Myasthenia Gravis
Conditions: Myasthenia Gravis Interventions: Device: Wearable sensor Sponsors: Massachusetts General Hospital; BioSensics Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 26, 2024 Category: Research Source Type: clinical trials
MuSK Myasthenia 1000 Study
Conditions: Myasthenia Gravis; MuSK MG; MuSK Myasthenia Gravis Sponsors: Myasthenia Gravis Rare Disease Network Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials
Medlink for Diagnosing of Diabetes Mellitus, COPD, CHF, Myasthenia Gravis and Hypertension
Conditions: Diabetes Mellitus; Chronic Obstructive Pulmonary Disease; Congestive Heart Failure; Myasthenia Gravis; Hypertension Interventions: Device: Medlink Sponsors: Olawuyi Racett Nigeria Ltd Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials
Myasthenia Gravis Registry in China
Conditions: Myasthenia Gravis Sponsors: Huashan Hospital; China Alliance for Rare Diseases; National Center for Neurological Disorders (China); China myasthenia gravis collaborating group (CMGCG) Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials
Johnson & Johnson Reports Positive Topline Results for Nipocalimab From a Phase 3 Pivotal Study in Generalized Myasthenia Gravis (gMG) and a Phase 2 Study in Sj ögren's Disease (SjD)
SPRING HOUSE, Pa., Feb. 5, 2024 /PRNewswire/ -- Johnson& Johnson today announced topline results from the pivotal Phase 3 VIVACITY study of nipocalimab in adults living with generalized myasthenia gravis (gMG) as well as the Phase 2 DAHLIAS... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - February 5, 2024 Category: Pharmaceuticals Source Type: clinical trials
Perioperative Efgartigimod for Thymoma and Myasthenia Gravis
Conditions: Myasthenia Gravis Interventions: Drug: Efgartigimod Alfa Sponsors: Shanghai Zhongshan Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 24, 2024 Category: Research Source Type: clinical trials
